P2 receptors and cancer

Trends in Pharmacological Sciences
Nicholas White, Geoffrey Burnstock

Abstract

Purinergic signalling has been implicated in many biological processes, and ATP and other extracellular nucleotides might have therapeutic potential in the treatment of cancer by signalling through P2 receptors. Different P2 receptor subtypes have been identified in a variety of different cancer types, in both primary samples of human cancer tissue and cell lines. Recent evidence suggests that different receptor subtypes mediate different pathophysiological functions such as proliferation, differentiation and apoptosis. In vivo studies of the use of ATP suggest that it can decrease the rate of cancer growth, and the first clinical trials have been undertaken. Thus, agents acting at P2 receptors might provide novel therapeutic tools in the treatment of cancer. In this article, background information about purinergic signalling and purinoceptor subtypes will be provided and then the proposed role of ATP in different cancers will be discussed in detail, including a discussion of in vivo studies and animal models, clinical trials and the specific P2 receptor subtypes involved.

References

Jan 1, 1990·Annals of the New York Academy of Sciences·E Rapaport
Mar 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·E Rapaport, J Fontaine
Sep 1, 1988·European Journal of Cancer & Clinical Oncology·E Rapaport
Sep 1, 1996·Medical and Pediatric Oncology·C M HaskellL Y Lee
Oct 29, 1998·Biochemical and Biophysical Research Communications·M HöpfnerH Scherübl
Apr 25, 2000·Molecular Human Reproduction·A Schultze-MosgauO Ortmann
Oct 4, 2000·The Journal of Biological Chemistry·M SolleC A Gabel
Dec 29, 2000·Molecular and Cellular Biochemistry·L van der WeydenM B Morris
Feb 13, 2001·British Journal of Pharmacology·R Janssens, J M Boeynaems
Mar 23, 2001·Trends in Pharmacological Sciences·F Di VirgilioP Illes
Mar 2, 2002·Clinical Medicine : Journal of the Royal College of Physicians of London·G Burnstock
Apr 15, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·Rainer SchaferGeorg Reiser
Jul 26, 2003·The Journal of Investigative Dermatology·Aina V H GreigGeoffrey Burnstock
Oct 11, 2003·Pharmacology & Therapeutics·Stefania MerighiPier Andrea Borea
Dec 19, 2003·Expert Opinion on Investigational Drugs·Kelly K NicholsDonald J Kellerman
Mar 6, 2004·Breast Cancer Research and Treatment·Michael SlaterJulian A Barden
Jun 17, 2004·Seminars in Vascular Medicine·Jean-Marc Herbert, Pierre Savi
Jul 23, 2004·American Journal of Physiology. Cell Physiology·Qifang WangGeorge I Gorodeski
Oct 12, 2004·Leukemia Research·Xiu-Jun ZhangKe-Fu Wu
Nov 19, 2004·International Review of Cytology·Geoffrey Burnstock, Gillian E Knight
Jan 22, 2005·American Journal of Physiology. Gastrointestinal and Liver Physiology·Robson Coutinho-SilvaGeoffrey Burnstock
May 25, 2005·Cancer Letters·Nicholas WhiteGeoffrey Burnstock
Jul 2, 2005·Cell and Tissue Research·Nicholas WhiteGeoffrey Burnstock

❮ Previous
Next ❯

Citations

Dec 4, 2013·Proceedings of the National Academy of Sciences of the United States of America·Damien LemoineThomas Grutter
Jun 18, 2014·The Journal of Clinical Investigation·Joonseok ChoByeong Chel Lee
Sep 3, 2014·Journal of Negative Results in Biomedicine·Laura BoldriniGabriella Fontanini
Sep 26, 2006·BMC Cancer·Fernanda B MorroneAna Maria O Battastini
Apr 7, 2009·Purinergic Signalling·Nicholas WhiteGeoffrey Burnstock
Nov 3, 2009·Molecular and Cellular Biochemistry·Elsie A OrellanoFernando A González
May 31, 2012·Purinergic Signalling·Marina Petersen GehringFernanda Bueno Morrone
Jun 5, 2012·Purinergic Signalling·Safina GadeockRonald Sluyter
Aug 17, 2010·Acta Pharmacologica Sinica·Lin MeiQi-bing Mei
Jun 27, 2009·Cancer Immunology, Immunotherapy : CII·Oscar J CorderoMontserrat Nogueira
May 1, 2012·Purinergic Signalling·Heike FrankePeter Illes
Jun 26, 2013·Purinergic Signalling·Geoffrey Burnstock, Francesco Di Virgilio
Aug 23, 2011·Molecular and Cellular Biochemistry·Angélica Regina CappellariAna Maria Oliveira Battastini
Jun 1, 2010·Current Microbiology·Ming LiJoo-Won Suh
Apr 10, 2013·Medical Oncology·Sasmit SarangiShiladitya Sengupta
Oct 24, 2007·Molecular Neurobiology·Kerstin WirknerPeter Illes
Mar 26, 2013·The International Journal of Biochemistry & Cell Biology·Jingqin FangWeiguo Zhang
Nov 22, 2008·Cell and Tissue Research·Elizandra BraganholAna Maria Oliveira Battastini
Oct 23, 2009·Expert Opinion on Therapeutic Targets·George I Gorodeski
May 30, 2014·Expert Review of Clinical Immunology·Sylvia Muller-HaegeleTheresa L Whiteside
Feb 18, 2016·Mediators of Inflammation·Sang Seong Kim
May 1, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Yibo ZhangTianfeng Chen
Mar 2, 2011·Molecular and Cellular Endocrinology·Han-jun LiBei Ma
Dec 3, 2014·Biochimica Et Biophysica Acta·Elizandra BraganholJean Sévigny
May 11, 2010·Archives of Biochemistry and Biophysics·Paola Scodelaro BilbaoRicardo Boland
May 11, 2010·European Journal of Pharmacology·Lijun LiuJunying Li
Nov 11, 2009·Archives of Biochemistry and Biophysics·Paola Scodelaro BilbaoGraciela Santillán
Jul 21, 2009·Molecular and Cellular Endocrinology·Sandra CasimiroJohn Chirgwin
Apr 18, 2009·Urologic Oncology·Joséli StellaAna Maria Oliveira Battastini
Nov 28, 2007·Cancer Letters·Wei WeiJames G McLarnon
Nov 22, 2007·Neurochemistry International·Herbert Zimmermann
May 27, 2014·Biochimica Et Biophysica Acta·Luiz Anastacio AlvesRobson Faria Xavier
Jun 29, 2007·Brain Research·Rodrigo A P Martins, Rachael A Pearson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Caspases in Metabolic Diseases

Caspases, the family of cysteine proteases are involved in programmed cell death, but their role in metabolic diseases, inflammation and immunity has been of interested. Discover the latest research on caspases in metabolic diseases here.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.